Discover investment opportunities in Best Pharma Stocks To Buy Now using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Pharma Stocks To Buy Now using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Pharma Stocks To Buy Now using our Smart AI Filter.
9 stocks found for "Best Pharma Stocks To Buy Now"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.59 Risk measure | ±31.6% Price volatility | 34.5 Valuation | 0.77% Annual yield | |||
0.35 Risk measure | ±28.9% Price volatility | 6.7 Valuation | 5.29% Annual yield | |||
0.45 Risk measure | ±20.5% Price volatility | 12.7 Valuation | 3.02% Annual yield | |||
0.33 Risk measure | ±27.9% Price volatility | 8.6 Valuation | 4.00% Annual yield | |||
0.32 Risk measure | ±24.8% Price volatility | 8.7 Valuation | 6.75% Annual yield | |||
0.37 Risk measure | ±19.7% Price volatility | 14.7 Valuation | 3.18% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
0.60 Risk measure | ±27.2% Price volatility | 15.6 Valuation | 3.47% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does Johnson & Johnson’s [JNJ] historical performance during economic downturns inform potential risk assessment?
A: Historically, Johnson & Johnson’s diversified product portfolio, including consumer health and pharmaceutical products, has helped it remain resilient during economic downturns. This suggests potential risk mitigation for investors looking for stability in the healthcare sector.
Q: What potential growth factors should investors consider for Pfizer [PFE]?
A: Investors may consider Pfizer's strong pipeline of drugs and vaccines, including the demand for COVID-19 treatments and innovations in other therapeutic areas. This has historically driven growth and could continue to provide opportunities.
Q: How might Merck & Co. [MRK] cater to income-seeking investors?
A: Merck & Co. offers attractive dividend yields, supported by a strong lineup of pharmaceuticals and consistent cash flow generation. Dividend stability may appeal to income-focused investors looking for reliable payouts.
Q: What are the sector-specific challenges faced by AbbVie [ABBV]?
A: AbbVie faces challenges like patent expirations, notably with Humira, which impacts revenue. However, its diversified product pipeline and acquisition strategies may offset this risk, presenting both challenges and opportunities for investors.
Q: Does Bristol-Myers Squibb [BMY] have a competitive advantage in oncology therapeutics?
A: Bristol-Myers Squibb is recognized for its strong oncology drug portfolio, including key products like Opdivo. This focus on cancer treatments offers competitive advantages in the growing oncology market, appealing to growth-minded investors.
Q: How does Eli Lilly [LLY] address the need for treatment innovation in diabetes care?
A: Eli Lilly is highly active in diabetes treatment innovation, driven by products like Trulicity and emerging therapies. This focus is critical as diabetes prevalence rises, offering potential growth opportunities for investors.
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read more